An add-on agent designed to boost drugs that treat age-related macular degeneration failed to show any benefit in two phase 3 ...

The European Commission has referred Eisai and Biogen’s application to an appeals committee. Elsewhere, Opthea warned of ...

Opthea Limited (CKDXF – Research Report) received a Sell rating and a A$0.05 price target from Bell Potter analyst Thomas Wakim yesterday. The ...

The veteran stockpicker told investors the firm would review how its $220 million wager on the biotech went so wrong “to ...

Grisly tales are emerging from the corridors of the US Food & Drug Administration (FDA) as mass sackings  take effect.

After announcing that lead candidate sozinibercept (OPT-302) failed the phase III Coast trial in wet age-related macular degeneration (AMD), Opthea has now decided to close the Coast trial as well as ...

Mach 7 and Universal Biosensors have announced their CEOs will depart, while changes at the top are likely at other biotechs.

Opthea has discontinued development of sozinibercept in wet age-related macular degeneration, according to a press release.

LifeMine restructures with layoffs; PTC's Translarna is pulled in Europe; Opthea ends AMD trials; Apollomics and LaunXP make ...

Opthea said it agreed with the investors in its development funding agreement to end development of sozinibercept in wet AMD, and that the move wouldn't constitute a termination event under the ...

The decision to discontinue the trials comes shortly after the announcement that COAST missed its primary endpoint.

Following the negative results of the COAST Phase III trial announced on 24 March, Australia-based Opthea announced has updated on its clinical program, including the termination of COAST (Combination ...